TIDMSLN

Silence Therapeutics PLC

14 May 2020

Silence Therapeutics to Participate in Fireside Chat at the RBC Capital Markets Global Healthcare Virtual Conference

14 May 2020

LONDON, Silence Therapeutics plc (LON: SLN) ("Silence" or "the Company"), a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, today announces that Dr. Rob Quinn, Chief Financial Officer, will be participating in a fireside chat at the 2020 RBC Capital Markets Global Healthcare Virtual Conference.

 
 
Date:      Wednesday, May 20, 2020 
Time:      10:55 am EDT (15:55 BST) 
Webcast    Silence Therapeutics fireside chat 
 link:

A live webcast of the event can be accessed via the Investors section of the Company's website at

www.silence-therapeutics.com . An archived replay of the webcast will be available for 60 days on the Company's website after the conference.

For more information, please contact:

 
 Silence Therapeutics plc                       Tel: +44 (0)20 3457 
  Iain Ross, Executive Chairman                  6900 
  Rob Quinn, Chief Financial Officer 
 Peel Hunt LLP (Nominated Adviser and Broker)   Tel: +44 (0)20 7418 
  James Steel/Oliver Jackson                     8900 
 European IR                                    Tel: +44 (0) 20 
  Consilium Strategic Communications             3709 5700 
  Mary-Jane Elliott/Chris Welsh/Angela Gray 
  silencetherapeutics@consilium-comms.com 
 U.S. IR                                         Tel: +1 (443) 213-0505 
  Westwicke 
  Peter Vozzo 
  peter.vozzo@westwicke.com

About Silence Therapeutics plc

Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, within its cells. Its proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-associated proteins. Silence's proprietary RNA chemistries and delivery systems are designed to improve the stability of molecules and enhance effective delivery to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases. The Company has secured high value research and collaboration agreements with AstraZeneca, Mallinckrodt Pharmaceuticals and Takeda. For more information, please visit: https://www.silence-therapeutics.com/

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

NRAAJMLTMTIBBLM

(END) Dow Jones Newswires

May 14, 2020 02:00 ET (06:00 GMT)

Silence Therapeutics (LSE:SLN)
Historical Stock Chart
From May 2024 to Jun 2024 Click Here for more Silence Therapeutics Charts.
Silence Therapeutics (LSE:SLN)
Historical Stock Chart
From Jun 2023 to Jun 2024 Click Here for more Silence Therapeutics Charts.